Balaji Prasad
Stock Analyst at Barclays
(2.85)
# 1,500
Out of 5,182 analysts
147
Total ratings
49.19%
Success rate
4.74%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $4.09 | +511.25% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $12.71 | -13.45% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $23.25 | +3.23% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $13.57 | -33.68% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $195.93 | +2.08% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $23.60 | -19.49% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $71.89 | -16.54% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $119.75 | +103.76% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $5.86 | +309.56% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $58.66 | -62.50% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $591.84 | -12.14% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $30.52 | -14.81% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $208.09 | -23.11% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $13.24 | +28.40% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $3.58 | +402.79% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $4.23 | +136.41% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.70 | +311.76% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $4.09
Upside: +511.25%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $12.71
Upside: -13.45%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $23.25
Upside: +3.23%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $13.57
Upside: -33.68%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $195.93
Upside: +2.08%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $23.60
Upside: -19.49%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $71.89
Upside: -16.54%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $119.75
Upside: +103.76%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $5.86
Upside: +309.56%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $58.66
Upside: -62.50%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $591.84
Upside: -12.14%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $30.52
Upside: -14.81%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $208.09
Upside: -23.11%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $13.24
Upside: +28.40%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $3.58
Upside: +402.79%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $4.23
Upside: +136.41%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.70
Upside: +311.76%